Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study Correspondence


Authors: Mailankody, S.; Salcedo, M.; Tavitian, E.; Burge, M.; Korde, N.; Hassoun, H.; Lesokhin, A.; Lahoud, O.; Smith, E.; Hultcrantz, M.; Tan, C.; Shah, U.; Devlin, S.; Landgren, O.
Title: Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
Keywords: clinical article; aged; fatigue; follow up; antineoplastic agent; prospective study; letter; progression free survival; multiple myeloma; antineoplastic combined chemotherapy protocols; maintenance therapy; dexamethasone; high risk patient; acute kidney failure; pilot study; pilot projects; urinary tract infection; comorbidity; lung infection; disease exacerbation; boron compounds; overall response rate; combination drug therapy; smoldering multiple myeloma; humans; human; boron derivative; ixazomib
Journal Title: Leukemia and Lymphoma
Volume: 63
Issue: 11
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2022-01-01
Start Page: 2760
End Page: 2761
Language: English
DOI: 10.1080/10428194.2022.2095626
PUBMED: 35838493
PROVIDER: scopus
DOI/URL:
Notes: Letter -- Export Date: 1 December 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hani Hassoun
    329 Hassoun
  2. Alexander Meyer Lesokhin
    363 Lesokhin
  3. Sean McCarthy Devlin
    601 Devlin
  4. Carl Ola Landgren
    336 Landgren
  5. Neha Sanat Korde
    226 Korde
  6. Oscar Boutros Lahoud
    133 Lahoud
  7. Meghan E Salcedo
    21 Salcedo
  8. Urvi A Shah
    187 Shah
  9. Carlyn Rose Tan
    130 Tan
  10. Miranda Burge
    12 Burge